NRx Pharmaceuticals, Inc. (NRXP)
NCM · Healthcare · Biotechnology
Closing price as of 2026-09-11 · Source: TEK2day Finance
Key Metrics
About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments. The company develops NRX-101, an oral fixed-dose combination of D-cycloserine (DCS) and lurasidone in Phase 2/3 clinical testing for bipolar depression with sub-acute ideation and behavior; NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression; and KETAFREE, a generic preservative-free formulation of ketamine. It also provides precision-based interventional psychiatry services to patients with treatment-resistant depression and PTSD using a combination of neuroplastic drugs, transcranial magnetic stimulation (TMS), digital therapeutics, and hyperbaric therapy; ketamine infusion therapy; stellate ganglion blocks; Spravato administration; psychotherapy; and medication management. The company has a development and license agreement with Glytech LLC. NRx Pharmaceuticals, Inc. was founded in 2015 and is headquartered in Wilmington, Delaware.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 242K | 983K | 1.1M | 1.1M |
| Gross Profit | 145K | 575K | 437K | 426K |
| Operating Income | (4.0M) | (4.6M) | (4.7M) | (6.5M) |
| Net Income | (5.9M) | 360K | (1.4M) | (16.5M) |
| Diluted EPS | $-0.27 | N/A | $-0.04 | $-0.44 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 1.2M |
| Gross Profit | 0.00 | 720K | ||
| Operating Income | (44.3M) | (27.6M) | (18.5M) | (16.2M) |
| Net Income | (39.8M) | (30.1M) | (25.1M) | (28.6M) |
| Diluted EPS | $-6.10 | $-3.98 | $-2.36 | N/A |